Published in AIDS Res Hum Retroviruses on May 29, 2013
Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay. AIDS (2014) 2.18
Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States. PLoS One (2013) 1.37
Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay. J Acquir Immune Defic Syndr (2014) 0.84
Determination of HIV Status in African Adults With Discordant HIV Rapid Tests. J Acquir Immune Defic Syndr (2015) 0.84
Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D. AIDS Res Hum Retroviruses (2014) 0.78
MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol (2011) 220.97
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA (1998) 9.32
Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses (2002) 7.03
Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis (2008) 4.48
Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol (1995) 3.44
Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS (2007) 3.26
Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol (2004) 2.94
HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis (2007) 2.87
Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses (2010) 2.86
Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill (2008) 2.66
Measuring the HIV/AIDS epidemic: approaches and challenges. Epidemiol Rev (2010) 2.53
Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis (2009) 2.43
HIV incidence in rural South Africa: comparison of estimates from longitudinal surveillance and cross-sectional cBED assay testing. PLoS One (2008) 2.35
Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 2.10
Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses (2008) 1.76
HIV-1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda. J Acquir Immune Defic Syndr (2010) 1.74
HIV incidence estimation using the BED capture enzyme immunoassay: systematic review and sensitivity analysis. Epidemiology (2010) 1.63
Errors in 'BED'-derived estimates of HIV incidence will vary by place, time and age. PLoS One (2009) 1.62
Estimating HIV incidence among adults in Kenya and Uganda: a systematic comparison of multiple methods. PLoS One (2011) 1.56
Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries. AIDS Res Hum Retroviruses (2012) 1.50
Changes in the distribution of HIV type 1 subtypes D and A in Rakai District, Uganda between 1994 and 2002. AIDS Res Hum Retroviruses (2010) 1.28
Effect of CD4+ T cell count and antiretroviral treatment on two serological HIV incidence assays. AIDS Res Hum Retroviruses (2011) 1.16
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Health professionals for a new century: transforming education to strengthen health systems in an interdependent world. Lancet (2010) 42.10
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet (2007) 37.69
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis (2005) 12.59
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med (2009) 8.26
Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet (2009) 6.80
Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS (2007) 5.97
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med (2012) 5.77
The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med (2002) 5.33
Untreated gonococcal and chlamydial infection in a probability sample of adults. JAMA (2002) 5.07
Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS (2009) 4.54
Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet (2005) 4.51
Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis (2008) 4.48
Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis (2013) 4.27
HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS (2011) 4.26
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 4.24
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS (2006) 4.23
The medical benefits of male circumcision. JAMA (2011) 4.05
Male circumcision for the prevention of acquisition and transmission of sexually transmitted infections: the case for neonatal circumcision. Arch Pediatr Adolesc Med (2010) 3.84
Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med (2010) 3.81
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol (2008) 3.60
Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis (2005) 3.59
Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. AIDS (2009) 3.53
Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet (2011) 3.52
Domestic violence in rural Uganda: evidence from a community-based study. Bull World Health Organ (2003) 3.45
Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. BMJ (2007) 3.41
Voluntary HIV counseling and testing acceptance, sexual risk behavior and HIV incidence in Rakai, Uganda. AIDS (2005) 3.39
Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol (2004) 3.36
The history and challenge of HIV prevention. Lancet (2008) 3.34
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30
Age differences in sexual partners and risk of HIV-1 infection in rural Uganda. J Acquir Immune Defic Syndr (2003) 3.11
Child mortality associated with reasons for non-breastfeeding and weaning: is breastfeeding best for HIV-positive mothers? AIDS (2003) 3.00
Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00
The contribution of HIV-discordant relationships to new HIV infections in Rakai, Uganda. AIDS (2011) 2.94